This study revealed that simvastatin enhanced the sensitivity of GC patients to immunotherapy, which led to further investigation of the role of simvastatin in promoting cytotoxic T-cell-mediated killing through ILF3-regulated PD-L1. Here, ILF3 is linked to gastric cancer.